NCT00400439View on ClinicalTrials.gov

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Coronary Heart Disease
Interventions
DRUG

dalcetrapib (RO4607381)

900mg po daily for 24 weeks

DRUG

placebo

po daily for 24 weeks

Trial Locations (9)

20817

Bethesda

28677

Statesville

40213

Louisville

45212

Cincinnati

45219

Cincinnati

46260

Indianapolis

52242

Iowa City

55455

Minneapolis

84132

Salt Lake City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00400439 - A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 | Biotech Hunter | Biotech Hunter